Skip to content

Intracutaneous suture versus transcutaneous skin stapling for closure of midline or horizontal skin-incision in elective abdominal surgery- A prospective randomized controlled single centered clinical trial to evaluate superficial surgical site infection

Intracutaneous suture versus transcutaneous skin stapling for closure of midline or horizontal skin-incision in elective abdominal surgery- A prospective randomized controlled single centered clinical trial to evaluate superficial surgical site infection - INTRANS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00004542
Enrollment
285
Registered
2012-11-19
Start date
2013-03-04
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T81.4

Interventions

Group 1: Control Group: Closure of skin using transcutaneous ski staples Group 2: Interventiongroup: Closure of skin using intracutaneous suture

Sponsors

Klinik für Viszeral-, Thorax- und Gefäßchirurgie Universitätsklinikum Gießen und Marburg- Standort Marburg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients scheduled for any elective abdominal surgery requiring midline or horizontal laparotomy, Age greater than 18 years; Expectancy of life greater than 12 months; Informed consent

Exclusion criteria

Exclusion criteria: Exclusion criteria are: date of admission exceeding four days prior to surgery, any antibiotic therapy within the 14 days prior to surgery, any previous midline or horizontal laparotomy if the procedure requires the same skin incision as before, neurophysiological or psychological deficiencies, participation in any other interventional trial that potentially interferes with the intervention or the results of the present trail, inability to understand the informed consent form.

Design outcomes

Primary

MeasureTime frame
The occurence of superficial surgical site infections is measured within 30 days after elective abdominal surgeries. Superficial surgical site infections are defined as category A1 according to the international CDC-classification. A1 infection are characterized by: Infection of the incision within 30 days after surgery, involving skin and subcutaneous tissue only and meeting one oft he following criteria: -Purulent secretion, cultural proof of bacteria derived from the tissue covering the incision or any secretion from the incision -One of the following clinical signs: pain or tenderness, swelling, redness, warmth -Opening of the wound by the treating surgeon -Diagnosed by the treating medical doctor On the days 2, 5, 10 and 30 after the elective operation Follow-Up visits are done and all wound are assessed according to the above named A1-criteria. Further, the extent of any antibiotic therapy is recorded (day 10). Patients with wound infections involving the abdominal wall or the itraabdominal cavity (CDC-Category A2 and A3) are treated as drop-outs and are excluded from the study since category A2 and A3 infections are unlikely to be associated with the examined procedures for skin closure.

Secondary

MeasureTime frame
The total operation time and the time of skin closure is measured during the operation. On day 30 after surgery, the cosmetic outcome is assessed on a subjective and objective basis on day 30 after surgery. A comprehensive self-explaining score accordingly to the German school note system ranging from 1-6 is used. Scoring is defined as follows: 1: very well, 2: good, 3: satisfactory, 4: unsatisfactory, 5: insufficient, 6: poor The subjective assessment is done by the patient using a self-explaining questionnaire. The objective assessment is done by an independent clinical expert separately. Moreover, the length of hospital stay and the duration of employees` illness are summoned and recorded in days on day 30 after surgery.

Countries

Germany

Contacts

Public ContactElisabeth Maurer

Klinik für Viszeral-, Thorax- und Gefäßchirurgie Universitätsklinikum Gießen und Marburg GmbH- Standort Marburg

maurere@med.uni-marburg.de06421-58-63690

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 21, 2026